James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Starbucks: Tasty, But Let It Cool First

Starbucks threw together a record-breaking bottom line in Q1, but the beat was far from convincing. It's still a slam-dunk stock -- you just shouldn't enter quite yet.

4 Tempting Dividends You MUST Resist

Don't get sucked in by these 4 dividend stocks. Behind their eye-popping yields lies the potential for disaster.

OPKO Health’s Healthy Buyout Binge

This healthcare name is rapidly building up a business worth watching. And the possibility of OPKO itself getting bought out isn't too remote.

Apple’s Q1 Earnings: It’s Not About Numbers

Ironically, the least important aspect of Wednesday's Apple Q1 earnings report might just be the earnings themselves.

Surprise! Dendreon Doesn’t Stink Anymore

It took three years, but this biotech may be quietly finding its footing as its innovative Provenge prostate-cancer fighter gains credibility.